EVIDENCE LIBRARY
Why Measure Both Withdrawal and Sedation After a PICU Medication Switch?
A medication transition can change comfort and sedation differently. A 2018 retrospective pediatric intensive-care study examined both withdrawal symptoms and sedation around conversion from intravenous midazolam to oral lorazepam.
Two sets of assessments
The study included 79 children. Investigators used the Sophia Observation withdrawal Symptoms scale and the COMFORT Behaviour scale, supplemented by nursing interpretation of sedation. Available withdrawal scores covered fewer children than the full cohort, while COMFORT-B scores were available for 77.
What the reported outcomes showed
Withdrawal was reported in 15 of 79 patients during the 48 hours before lorazepam began and 17 of 79 during the 48 hours afterward. In the 24-hour periods immediately before and after substitution, oversedation was reported in 16 and 30 patients, respectively. The withdrawal and sedation summaries therefore concerned different outcomes and observation windows.
What to preserve in an individual review
The before-and-after design lacked a randomized comparison group. Other sedatives and analgesics were also used, and incomplete scoring affected ascertainment. Similar recorded withdrawal proportions alone leave the overall sedation experience unresolved. For families or attorneys reviewing a PICU course, the conversion time, actual administrations, concurrent drugs, rescue doses, and individual score trajectories help explain what happened. This study’s findings concern a specific institutional protocol and cohort. Its value for interpretation comes from examining withdrawal and sedation separately, with their measurement limits intact.